MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Pleural

Malignant pleural mesothelioma; mesothelioma of the lining of the lungs, or pleura.

A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma.

Lung Cancer 2020 February 12 [Link] Zucali PA, Perrino M, De Vincenzo F, Giordano L, Cordua N, D’Antonio F, Santoro A Abstract OBJECTIVES: Second-line chemotherapy is not a standard of care in patients with malignant pleural mesothelioma (MPM) that progresses after first-line treatment with cisplatin and pemetrexed. In pre-clinical models, the combination of gemcitabine (GEM) […]

Comments Off on A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma.

Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma.

Journal of Immunotherapy for Cancer 2020 February [Link] Hotta K, Fujimoto N Abstract Platinum-based chemotherapy is commonly used as the standard first-line treatment for unresectable malignant pleural mesothelioma (MPM). However, in recent times, immune-checkpoint inhibitors (ICIs) have led to a paradigm shift. Herein, we review relevant literature and ongoing trials of ICIs used as both […]

Comments Off on Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma.

The role of imaging in malignant pleural mesothelioma: an update after the 2018 BTS guidelines.

Clinical Radiology 2020 February 18 [Link] Sinha S, Swift AJ, Kamil MA, Matthews S, Bull MJ, Fisher P, De Fonseka D, Saha S, Edwards JG, Johns CS Abstract Malignant pleural mesothelioma (MPM) is a primary malignancy of the pleura and is associated with a poor outcome. The symptoms and signs of malignant mesothelioma present late […]

Comments Off on The role of imaging in malignant pleural mesothelioma: an update after the 2018 BTS guidelines.

Genetic alterations of malignant pleural mesothelioma: association to tumor heterogeneity and overall survival.

Molecular Oncology 2020 February 21 [Link] Quetel L, Meiller C, Assié JB, Blum Y, Imbeaud S, Montagne F, Tranchant R, de Wolf J, Caruso S, Copin MC, Hofman V, Gibault L, Badoual C, Pintilie E, Hofman P, Monnet I, Scherpereel A, Le Pimpec-Barthes F1, Zucman-Rossi J, Jaurand MC, Jean D Abstract Development of precision medicine […]

Comments Off on Genetic alterations of malignant pleural mesothelioma: association to tumor heterogeneity and overall survival.

Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16).

Annals of Oncology 2020 January 16 [Link] Metaxas Y, Früh M, Eboulet EI, Grosso F, Pless M, Zucali PA, Ceresoli GL, Mark M, Schneider M, Maconi A, Perrino M, Biaggi-Rudolf C, Froesch P, Schmid S, Waibel C, Appenzeller C, Rauch D, von Moos R; Swiss Group for Clinical Cancer Research (SAKK). Abstract BACKGROUND: Systemic second- […]

Comments Off on Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16).

Disease-Related Outcomes and Toxicities of Intensity-Modulated Radiation Therapy Following Lung-Sparing Pleurectomy for Malignant Pleural Mesothelioma: A Systematic Review.

Practical Radiation Oncology 2020 February 20 [Link] Patel R, Ludmir EB, Miccio JA, Menon H, Barsky AR, Mesko SM, Kodali M, Lautenschlaeger T, Adeberg S, Simone CB 2nd, Verma V Abstract PURPOSE: To explore the use of intensity-modulated radiotherapy (IMRT) after lung-sparing surgery in malignant pleural mesothelioma (MPM). Because severe toxicities have been documented following […]

Comments Off on Disease-Related Outcomes and Toxicities of Intensity-Modulated Radiation Therapy Following Lung-Sparing Pleurectomy for Malignant Pleural Mesothelioma: A Systematic Review.

Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement.

Lung Cancer 2020 February 14 [Link] Bronte G, Delmonte A, Burgio MA, Verlicchi A, Puccetti M, Bravaccini S, Cravero P, Tumedei MM, Diano D, Rossi G, Ulivi P, Martinelli G, Crinò L Abstract OBJECTIVES: Treatment options for malignant pleural mesothelioma (MPM) are limited but some studies on immune checkpoint inhibitors (ICIs) in MPM have reported […]

Comments Off on Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement.

An in vivo immunohistochemical study on MacroH2A.1 in lung and lymph-node tissues exposed to an asbestiform fiber.

Current Molecular Science 2020 February 20 [Link] Loreto C, Lombardo C, Caltabiano R, Ledda C, Hagnas M, Filetti V, Rapisarda V Abstract AIMS: The aim of this study was to investigate MacroH2A.1 immunoexpression in tissues of sheep exposed to FE. BACKGROUND: The correlation between asbestiform fibers, lung cancer, pleural mesothelioma and other lung diseases is […]

Comments Off on An in vivo immunohistochemical study on MacroH2A.1 in lung and lymph-node tissues exposed to an asbestiform fiber.

Survival of malignant mesothelioma and other rare thoracic cancers in Germany and the United States: A population-based study.

International Journal of Cancer 2020 February 18 [Link] Sirri E, Kieschke J, Vohmann C, Katalinic A, Nennecke A, Ressing M, Eberle A, Holleczek B, Jansen L, Brenner H; GEKID Cancer Survival Working Group Abstract Evidence on survival of malignant mesothelioma (MM) and other rare thoracic cancers is limited due to the rarity of these cancer […]

Comments Off on Survival of malignant mesothelioma and other rare thoracic cancers in Germany and the United States: A population-based study.

Lung Asbestos Fibre Burden and Pleural Mesothelioma in Women with Non-occupational Exposure.

Annals of Work Exposure and Health 2020 February 17 [Link] Barbieri PG, Somigliana A, Chen Y, Consonni D, Vignola R, Finotto L Abstract BACKGROUND: Malignant pleural mesothelioma (MPM) due to environmental and familial (domestic) asbestos exposure is well recognized. However, information on cumulative asbestos dose in subjects affected by MPM is limited. OBJECTIVES: To evaluate […]

Comments Off on Lung Asbestos Fibre Burden and Pleural Mesothelioma in Women with Non-occupational Exposure.